Core Viewpoint - The FDA is taking action against companies selling generic weight loss drugs, specifically targeting Hims & Hers Health, which recently began offering a discounted version of Novo Nordisk's Wegovy [1][3]. Group 1: Regulatory Actions - The FDA's Director, Dr. Robert Califf, stated that actions are aimed at protecting consumers from drugs whose quality, safety, or efficacy cannot be verified by the FDA [1]. - The U.S. Department of Health and Human Services (HHS) has referred Hims to the Department of Justice for investigation under the Federal Food, Drug, and Cosmetic Act [3]. - Novo Nordisk expressed support for the actions taken by HHS and FDA to protect patients from unapproved generic drugs that may pose significant safety risks [3]. Group 2: Market Reactions - Novo Nordisk's ADR rose by 5.1% in after-hours trading, while Hims' stock fell by approximately 13% [2]. - Hims and other telehealth companies had previously capitalized on the opportunity to sell low-cost generic versions of weight loss injections during a period of widespread shortages, which have now ended [2]. Group 3: Company History and Relationships - Novo Nordisk and Hims have a complicated history, having previously collaborated to offer a discounted version of Novo Nordisk's injection weight loss drug, which ended after two months due to accusations of misleading marketing by Hims [4]. - Eli Lilly expressed appreciation for the FDA's actions and looks forward to further regulatory measures against misleading drug advertisements [4].

Group 1 - Novo Nordisk's stock price surged over 5% in early European trading after the FDA committed to addressing the large-scale marketing of unapproved weight loss pills, recovering some of the losses from the previous two trading days [1] - In pre-market trading, Novo Nordisk's ADR (NVO.US) rose by more than 8%, while Eli Lilly (LLY.US) rebounded nearly 4% after a previous drop of almost 8% [1] - The FDA's Director, Marty Makary, announced on social media that the agency would take swift action against companies marketing illegal generic weight loss drugs, emphasizing the inability to verify the quality, safety, or efficacy of unapproved medications [1] Group 2 - Wegovy Pill, the world's first oral macromolecule drug for weight loss, was launched in the U.S. at the beginning of the year and quickly became a star product in the obesity market, with prescriptions increasing from 3,071 in the first four days to over 18,000 by January 16, and further to 26,109 by January 23, demonstrating strong market momentum [2] - Patients with chronic diseases, including obesity and diabetes, tend to prefer oral medications over injections, which is crucial for treatment adherence and achieving therapeutic efficacy [2]